For the roughly 12 million Americans who receive care at home each year, most of them older adults managing chronic conditions, heart failure, COPD, dementia, recovery from a hip replacement, the visit that matters is the one a nurse makes in their living room. What happens after that visit is where home health agencies tend to lose money and lose sleep: hours of charting, OASIS assessments, intake paperwork, and coding that has to satisfy Medicare conditions of participation before a single claim gets paid. Enzo Health, a 2023-founded startup based in Lehi, Utah, is building an AI documentation co-pilot aimed squarely at that back-office burden, with a product the company describes as HIPAA-compliant and purpose-built for home care services [Enzo Health, 2024].
The patient population here is specific and worth naming. Home health and post-acute care serve people who are medically homebound, often after a hospital discharge, and who depend on intermittent skilled nursing, physical therapy, or home health aide visits to avoid readmission. The standard of care today is a hybrid of in-home clinical assessment and an electronic medical record workflow built around CMS-mandated forms, most notably the OASIS-E assessment that drives reimbursement under the Patient-Driven Groupings Model. Agencies typically run on incumbents such as Netsmart, Homecare Homebase, or WellSky, and quality assurance nurses spend significant time reviewing clinician notes for coding accuracy and compliance before submission. It is slow, it is expensive, and it is one of the largest non-clinical cost centers in the sector.
Enzo's bet is that a documentation co-pilot can sit alongside (or eventually inside) those workflows and compress the administrative tail of each visit. The company markets an "all-in-one documentation, intake, and coding software for home care services" [Enzo Health, 2024], and Crunchbase describes the product more plainly as "a documentation co-pilot for post-acute healthcare" [Crunchbase, 2024]. The wedge appears to be agency owners who feel the squeeze of PDGM reimbursement and rising labor costs, and who want compliance automation that also recovers revenue lost to under-coding. Tandem Ventures, one of Enzo's backers, frames the value proposition as giving "agency owners compliance automation while increasing revenue" [Tandem Venture Partners, 2024].
The market tailwinds are real. Home-based care is one of the fastest-growing segments of U.S. healthcare, propelled by an aging population, payer preference for lower-cost settings, and CMS payment models that increasingly route post-acute spend through home health rather than skilled nursing facilities. Generative AI applied to clinical documentation has had a credible early showing in adjacent categories, ambient scribes for primary care being the most visible example, and investors have started looking for the equivalent in post-acute settings, where margins are thinner and EMR tooling has historically lagged. Enzo's $1.5 million pre-seed, closed in May 2024, came from Soma Capital and Tandem Ventures, with the company also passing through Soma Fellows' S24 cohort [Crunchbase, May 2024] [Soma Fellows, 2024]. Tandem has since announced a $50 million Fund I, suggesting Enzo's lead-stage backers have more capital available to support follow-on rounds [Utah Business, 2025].
Pre-seed raised | 1.5 | $M
Tandem Ventures Fund I | 50 | $M
Founder Zach Newman is building the company out of Lehi, a corridor that has produced a steady stream of vertical SaaS companies serving regulated industries. Enzo recently announced an advisory board of home-based care industry leaders intended to drive credibility and partnerships in the sector [Business Wire, 2025], a move that matters in a market where reference customers and regulatory fluency tend to gate enterprise adoption more than raw product quality. The company is also hiring on the clinical side: a current opening for a PRN Quality Assurance Nurse [AshbyHQ, 2026] suggests Enzo is keeping nurses in the loop on QA, both to train and validate model output and to sell credibly to agency clinical leadership.
What bears will say is straightforward. The incumbent home health EMRs, Netsmart chief among them per Enzo's own competitive framing, are entrenched, integrated with billing, and difficult to displace at the agency level even when the user experience is dated. AI documentation is also becoming a crowded category across healthcare, and a pre-seed company will need to show that a vertical focus on home health produces materially better accuracy on OASIS coding and visit notes than a generalist scribe pointed at the same workflow. What bulls will answer is that home health is precisely the kind of niche where horizontal tools tend to underperform: the forms are idiosyncratic, the reimbursement logic is unforgiving, and the buyers are mid-market agency operators who do not get prioritized by the large EMR vendors. A product built natively for OASIS-E and PDGM, with QA nurses in the loop, is a defensible wedge if Enzo can convert early agencies into measurable revenue lift and clean audit outcomes.
The next twelve months are about evidence. Watch for Enzo to publish, or for early customer agencies to publicly attest to, concrete numbers on documentation time saved per visit, coding accuracy improvements, and any reduction in claim rejections or ADR (additional documentation request) burden. A seed round on the back of named agency customers would be the natural next step, particularly with Tandem's larger fund now in market. Partnership announcements with an existing home health EMR, or integration into a billing clearinghouse, would signal that Enzo intends to live alongside incumbents rather than replace them outright.
The disease states sitting behind all of this, heart failure, COPD, post-surgical recovery, dementia, are not going to get less common, and the nurses caring for those patients in their homes are not going to get less scarce. If Enzo can give those clinicians back even thirty minutes a visit without compromising what ends up in the chart, the patient outcome story writes itself.
Pulse Raman, Health and Bio Correspondent, Startuply.